Arie Belldegrun Transfers Shares of Allogene Therapeutics Inc (ALLO) — SEC Form 4, Apr 01, 2022

This is an amended filing (Form 4/A) — it supersedes the original filed March 31, 2022.

SEC Form 4 · No Market Transaction

Other Transaction

Non-market transaction reported.

Reporting Owner

Arie Belldegrun

Director

TXN 2022-03-14 · FILED 2022-04-01

Equity Position 5.08M sh 5,082,030 → 5,082,030

Filing Lag 14 business days late vs 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

Allogene Therapeutics Inc

ALLO CIK 0001737287

Reporting Owner

Name	Relationship
Arie Belldegrun CIK 0001296549	Director

Arie Belldegrun at Allogene Therapeutics Inc Full insider history

Bought (12 mo) —

Sold (12 mo) —

More from this insider at Allogene Therapeutics Inc

Non-Derivative Securities Transactions

Title	Date	Type	Shares	Price	Net Total	Post-Txn	Ownership
Common StockF2	2022-03-14	J - Other	4,710,120 D	$0.00	—	0	Indirect
Common StockF1 F2	2022-03-14	J - Other	4,710,120 A	$0.00	—	4,710,120	Indirect

Non-Derivative Holdings

Title	Shares Held	Ownership
Common StockF1	371,910	Direct

Footnotes (2)

F1: This amendment is being filed to correct the share holdings reported on the Form 4 filed by the reporting person on March 31, 2022. Show more
F2: These shares were sold by Bellco Legacy IV LLC, of which the reporting person and Rebecka Belldegrun are managers, to Bellco Legacy Trust fbo Rebecka Belldegrun, of which the reporting person's spouse is trustee and beneficiary. In exchange for the shares, the reporting person received a promissory note in the principal amount of $36,032,418.00. Show more

Institutional Holders

Largest by reported value

5%+ Holders · 13D/G 4 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at Allogene Therapeutics Inc

GET /v1/forms/4/0001214659-22-004729 API docs